MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c), which is a peptide consisting of 16-amino acids, is encoded by mitochondrial DNA instead of nuclear DNA like the majority of signaling peptides derived from the nuclear genome. With this origin of MOTS-c, it is one of the very few mitochondrial-derived peptides (MDP) that play a vital role in signaling the metabolic condition from the mitochondria to the cell and throughout the body.
The term "exercise mimetic" originates from a simple fact observed: MOTS-C levels increase after acute physical exercise in people, and application of exogenous MOTS-C in animal models can achieve similar metabolic effects as exercise training, including improved insulin sensitivity and fat storage reduction. That makes it possible to study MOTS-C simultaneously with the subject of peptides for metabolism and compare it to AOD-9604.
The main signaling node in MOTS-c is AMPK, or AMP-activated protein kinase, the cellular energy sensor that becomes activated when levels of AMP rise compared to ATP, which happens during physical exercise or calorie restriction. In previous studies, it was shown that MOTS-c moves to the nucleus upon metabolic stress where it initiates nuclear gene expression in an AMPK-dependent manner, thus confirming the role of the peptide not only as a circulating signal but also as an active gene expression regulator. This nuclear translocation feature distinguishes MOTS-c from most of the other metabolic peptides including AOD-9604, which works at the periphery in the body via activation of beta-3 adrenergic receptors located in adipose tissue.
The connection between the folate cycle and the methionine cycle is not yet widely known but it is relevant. Disruption of the cycle by MOTS-c reduces the synthesis of purines required for de novo lipogenesis, thereby giving it a secondary effect of anti-fat accumulation in addition to activating AMPK. The combined effect of the two pathways is what leads the researchers to say about the broad metabolic effect of MOTS-c and not necessarily targeted.
A 2024 review confirmed that with increasing age, MOTS-c expression declines while it increases when exercising. This supports the theories of longevity and exercise mimicry. Decrease in circulating MOTS-c with aging coincides with impaired insulin sensitivity and mitochondrial dysfunction. It is, however, yet unclear whether one causes the other.
The best proof of MOTS-c is in its role in regulating metabolism and, in particular, in its ability to enhance insulin sensitivity. Experiments performed in mouse models of the disease have demonstrated that administration of MOTS-c reverses the insulin resistance caused by obesity and allows for reductions in fat deposition without any changes in food intake - thus providing a mechanism that is entirely different from the action of GLP-1 receptor agonists such as semaglutide or tirzepatide, which act mainly through suppression of appetite.
Data on exercise capacity derived from rodent studies reveal enhanced endurance and skeletal muscle glucose uptake. Aged mice administered with MOTS-c experienced improvements in physical performance that young mice did not, implying that the effect might be more significant when baseline MOTS-c levels are low, as in older individuals. Studies on healthspan in older mice suggested decreased age-related weight gain and improved metabolic markers, although “healthspan” in the mouse model is quite a step away from making any claims about human longevity.
What counts as non-human data: everything mentioned in the previous paragraphs. As of June 2026, there hasn’t been a peer-reviewed randomized controlled trial in humans indicating that exogenous MOTS-c can improve insulin response, lessen obesity, and prolong one’s health. The supposed benefits of MOTS-c for exercise ability and weight loss are taken from animal studies and understanding of AMPK activation. It should be stated this way, as there is a lot of content on MOTS-c in publications and online that does not mention that.
A certain variant of MOTS-c known as (K14Q) appears in a significantly higher proportion among those who have reached the age of 100 years in Japan showing the biological capability of the peptide to boost ones' longevity in life. However, finding genetic association of a polymorphism in a population is different from potential therapeutic benefit. We would like to emphasize it as this is always of great interest to researchers pursuing knowledge about this peptide.
Two clinical programs are the reference points for human MOTS-c data. CohBar’s CB4211 was the first Phase 1b/2a trial to test a modified version of MOTS-c and not its native form in people with NASH and diabetes. It established a baseline for both safety and tolerability of the compound class; however, it has different pharmacokinetics from the native MOTS-c and the dosing cannot be generalized.
The trial most related to the current one is the MOTS-MET Phase 2a randomized, double-blind, placebo-controlled trial (NCT07505745), whose aim is to administer 12 weeks of subcutaneous native MOTS-c compared to placebo in adults with prediabetes, where the main outcome will be insulin sensitivity. This trial is expected to produce the first controlled human data on the metabolic effects of native MOTS-c. Although the trial dose and schedule have not been publicly disclosed, the 12-week subcutaneous design is in accordance with most research protocols.
The issue of the difference between the dosage in clinical trials and that indicated in the community protocols is common for peptides. In the case of MOTS-c, community protocols suggest doses of 5-10 mg per week in 2-3 subcutaneous injections while clinical dose is based on the pharmacokinetic modelling data from Phase I studies. The dosage from the community protocol remains merely a guess until the results of MOTS-MET become available.
The table displays the dosing schema given by research studies and also community research references. The table is valid specifically for laboratory research. The calculations in this table have assumed that bacteriostatic water has been used for reconstitution.
| Weekly Total | Injections / Week | Per Injection | 10 mg Vial (2 ml BAC) - Units/Injection | 20 mg Vial (4 ml BAC) - Units/Injection |
|---|---|---|---|---|
| 5 mg | 2. | 2.5 mg. | 50 units (0.50 ml). | 50 units (0.50 ml). |
| 7.5 mg | 3. | 2.5 mg. | 50 units (0.50 ml). | 50 units (0.50 ml). |
| 10 mg | 2. | 5 mg. | 100 units (1.00 ml). | 50 units (0.50 ml). |
| 10 mg | 3. | 3.3 mg. | 67 units (0.67 ml). | 33 units (0.33 ml). |
Please observe that the term "units" indicates compliance with the insulin syringe measurement stating that 100 units equal 1.0 ml. Each vial mentioned above has 5 mg/ml concentration, which translates to 10 mg in 2.0 ml and then, 20 mg in 4.0 ml usage meaning all vials measure the same number of units of insulin as established in the previous paragraphs accordingly.
Research protocols usually describe subcutaneous injection during fasting, either in the morning or 30-60 minutes prior to exercising, as reasoning suggests that both exercise-related AMPK activation and MOTS-c may work in concert. While there is no data on the timing in humans, this mechanistic rationale is in accordance with the general studies done on AMPK-activating agents.
In research protocols, cycle duration falls between four to eight weeks, but MOTS-MET trial takes an exception with a 12 week cycle period. Without any published evidence, there is no affirmative indication showing cycle length longer than 12 weeks for native MOTS-c. No separate protocol is indicated for women, and studies show that dosing of medications occurs equally for male and female populations.
Preparation: gradually incorporate bacteriostatic water into the powdered material, mixing adequately but avoiding undue agitation. The reconstituted vial should be preserved at a temperature of 2-8 degrees. The powdered material should be kept cool, dry, and protected from light prior to use. The universal research technique requires injection in the subcutaneous abdominal area, as currently available evidence does not indicate any local benefits from injecting near designated fat sites. Always use peptide dosage calculator to ensure proper dosage measurement for each injection.
While research data on the side effect profile of MOTS-c suggests these side effects are not absent, they are also modest. The most commonly reported side effects are those from the injection site, which include redness, mild swelling, and temporary pain. Other side effects mentioned in a few reports include the feeling of low blood sugar characterized by dizziness or fleeting fatigue, which makes sense due to the mechanism of action of MOTS-c that contributes to glucose uptake and AMPK activation.
Researchers have reportedly noted instances of palpitations and difficulty sleeping with high doses of this treatment. While not specifically mentioned in clinical trials, these side effects are consistent with the way AMPK works in the body. Most researchers indicate that these symptoms decrease when doses are lowered.
The significant safety advice refers to the whole category: there is no long-term human safety data for the naturally occurring MOTS-c. The CB4211 Phase 1b/2a study has observed short-term tolerability of its analog rather than native MOTS-c and the MOTS-MET trial lasts 12 weeks. What happens after this period is unknown. It does not mean that the compound should not be used but it is an indication of how to interpret the term "safe" in this case.
The use of MOTS-c is not recognized by the FDA as a medication. Up to now, there have been no approved applications of drugs that contain the MOTS-c. The CB4211 program conducted a study involving the analogue with results that were not eligible for NDA submission. Therefore, every fluid that contains MOTS-c in the US is considered a research fluid, and no medicine can be exported.
The 503A compounding question perplexes so many in 2026. The FDA's compounding safety framework determines which one of the following categories individual substances fall into: Category 1 (can be compounded), Category 2 (cannot be compounded), or under review. AOD-9604 was classified as Category 2 in September 2023, meaning that compounding pharmacies can no longer compound it legally. The status of MOTS-c under 503A is still under review in the middle of 2026, meaning it occupies a different regulatory position from AOD-9604 at this time, although things could change. Researchers and institutions need to check the present status before sourcing.
It is important to mention the GRAS analogy at this point as it also appears in the negotiations of AOD-9604 and sometimes shifts over into MOTS-c discussions. AOD-9604 was labeled as GRAS by FDA (Generally Recognized As Safe) when used as a food ingredient in 2014. GRAS means that FDA determined its safety at the doses in food application - however, it does not mean it is a sanctioned drug, it does not allow for making any therapeutic claims, and it does not annul the ban on 503A compounding. MOTS-c has not received the GRAS label. One should keep in mind that the two regulatory procedures differ and they are not interchangeable.
In America, it can be stated that adults 21 years of age or older can purchase MOTS-c legally as a research chemical in laboratories. It cannot be sold with regard to any human therapeutic use, it cannot be compounded by 503A pharmacies while its status is under review, and it is not available as a prescription drug. The possession for personal consumption lies in the legality gray area that differs from state to state; the research-use framework is the only acceptable commercial position available.
For competitive athletes, the answer is clear. WADA's Prohibited List recognizes the MOTS-c under S4.4.1 as a stimulant of AMPK, which is banned at all times whether during or outside of competition. USADA adheres to the WADA list of prohibited substances and does not offer Therapeutic Use Exemptions (TUEs) for MOTS-c as there is no approved medical use for it. Any athlete who is covered by WADA or USADA must refrain from using MOTS-c regardless of its source.
AOD-9604 falls under Category S2 according to WADA guidelines. The fact that this compound is classified as a GH fragment distinguishes it from the other component in Category S4.4. The two compounds fall under distinct places in the same list and this implies that they each have their own potential mechanisms for action. Since NCAA has adopted the same framework for prohibited substances as WADA, NCAA colleges also prohibit collegiate athletes from using AOD-9604.
Researchers often inquire about the position of MOTS-c in comparison to AOD-9604 and the secretagogues of growth hormone with regards to the fatty acid metabolism and metabolism-modifying peptide studies. The following table provides the complete information needed for such comparisons, indicating the mechanism of action, status of human studies, and the regulatory status of the peptides. For those interested in a more detailed analysis of AOD-9604, the information is discussed in detail in the link provided above.
| Compound | Primary Mechanism | Human RCT Data? | IGF-1 Effect | WADA Status | 503A Compounding (2026) |
|---|---|---|---|---|---|
| MOTS-c | AMPK activation, nuclear translocation, folate cycle disruption. | Phase 2a ongoing (NCT07505745). | No effect. | Prohibited S4.4.1. | Under review. |
| AOD-9604 | Beta-3 adrenergic lipolysis, inhibits lipogenesis. | Phase 2 complete; no significant weight loss. | No effect. | Prohibited S2. | Category 2 (banned). |
| SLU-PP-332 | ERR-alpha/gamma agonist, mitochondrial biogenesis. | No human data. | No direct effect. | Not yet listed (as of 2026). | Not nominated. |
| AICAR | AMPK activation (AMP analog). | Limited; used in metabolic research. | No direct effect. | Prohibited S4.4.1. | Category 2. |
| CJC-1295 / Ipamorelin | GHRH + ghrelin receptor; raises GH pulse. | CJC-1295 Phase 1/2; Ipamorelin Phase 1. | Raises IGF-1. | Prohibited S2. | Category 2. |
The fundamental difference between the two compounds, MOTS-c and AOD-9604, is that while AOD-9604 targets adipose tissue via beta-3 adrenergic receptors, MOTS-c operates via AMPK and mitochondrial pathways systemically. Neither of these compounds affects IGF-1 levels in the body, which is a shared advantage they have over GH or IGF-1 promoters. AOD-9604 has undergone a clinical trial that proved it is safe, although the compound was not effective concerning weight loss. The compound has also been placed in category 503a, while the other one is still undergoing review.
The stacks that most frequently appear in protocols used in research related to mitochondrial health are combinations of MOTS-c and other chemical products that work on mitochondria or NAD+ metabolism. The reasoning is straightforward: if MOTS-c sends out information about the metabolic stress created in mitochondria, then substances that enhance the functioning of mitochondria or gens availability of NAD+, may strengthen the effect that it creates.
NAD+ precursors (such as NMN and NR) are frequently mentioned as co-administered substances owing to their working through the same AMPK-SIRT1 mechanism. SS-31 (elamipretide) is a mitochondrial-specific antioxidant peptide with decremented mitochondrial oxidative stress; therefore, the combination of SS-31 and MOTS-c demonstrates coherent rationale in studies of aging or metabolic disorders, although this combination of substances has never been scientifically tested in humans.
5-Amino-1MQ is an NNMT inhibitor that works at the level of small molecules and increases the levels of SAM and NAD+ in fat tissue. Its mechanism differs from the AMPK pathway used by MOTS-c, providing a multi-target method of fat metabolism in studies. We have 5-Amino-1MQ available at US Peptide Labs starting at $62.00 for researchers using this approach.
One thing we have observed from many researchers contacting us is the tendency to use three to four mitochondrial compounds at the same time. This method is inefficient from the view of the research design because it is impossible to distinguish the effects of each compound used in the experiment. However, a better strategy is using a combination of two compounds followed by a washout period.
You can order MOTS-c from US Peptide Labs in the form of lyophilized vials for $95.00 each. Each vial comes with an AxisPharm COA that certifies the product's authenticity and quality. There is free shipping in the US for orders of $70 and above. Bulk discounts are offered when buying two or more vials (5%) and five or more vials (10%). All buyers must be 21 years of age.
The claim of "99% purity" on Certificates of Analysis deserves a simple clarification as this is the most misused number in the field of peptide sourcing. Purity by HPLC means that the target peptide constitutes 99% or more of the UV-absorbing material present in a sample, but it does not mean that 99% of the total weight of a vial consists of just the active peptide. The lyophilized peptide vials consist of excipients, residual solvents, and water of crystallization that are not taken into consideration when calculating HPLC purity. A 10 mg vial with 99% HPLC purity doesn’t necessarily have 9.9 mg of active peptide. Certificates of Analysis should also contain mass specifications which confirm the chemical identity and preferably the results of endotoxins testing, too. The instructions on how to read every part of the COA are provided in COA reading guide , where you can also see what AxisPharm states in the COA of its products quality COAs page .
On the subject of vial size: a 10 mg vial that has been reconstituted with 2 ml gives a concentration of 5 mg/ml, meaning that if used at the rate of 2.5 mg per injection, it can result in 4 injections, or two weeks of use at a frequency of 2 times a week. A 20 mg vial reconstituted in 4 ml has the same concentration and allows for 8 injections, meaning 4 weeks of use at the same frequency. Therefore, for an 8-week cycle at the rate of 5 mg/week (2 injections), using two 20 mg vials is sufficient. It is the calculations regarding the vials rather than their price which are more useful in terms of planning a research cycle.
As of late 2026, US Peptide Labs does not have any inventory of its AOD-9604 SKU, as the implementation of 503A Category 2 status in 2023 has changed the dynamics of acquisition of the items. In the catalog of US Peptide Labs one will find various fat metabolizing agents, such as Tirzepatide at the price of $76, Tesamorelin at the price of $92 and MOTS-c for $95 that will meet the research focus.
MOTS-c is evaluated for its influence on insulin sensitivity, glucose metabolism, fat storage, endurance capacity, and metabolic aging decline in studies. It is a peptide encoded within the mitochondria that activates AMPK and moves to the nucleus, where it controls gene expression during metabolic stress. It has not received approval to be used therapeutically in humans and can only be purchased for laboratory usage.
Research protocols talk of administering 5-10 mg weekly using 2-3 subcutaneous injections. Administering the drug is most common in fasting state either in the morning or before exercising given the mechanistic pathways for exercise-induced AMPK activation are similar to the action mechanism for MOTS-c. These protocols are just parameters of research; clinical dosing recommendations have to be established separately. Please check the peptide dosage calculator for vial-specific unit draws.
In rodent experiments, the use of MOTS-c was associated with a decrease in fat accumulation and a reversal of obesity due to a high-fat diet despite no change in food intake. No randomized controlled trials have been conducted in humans, evaluating the impact of MOTS-c on weight loss. The primary objective of the MOTS-MET Phase 2a trial (NCT07505745) is insulin sensitivity rather than weight loss. Therefore, the evidence available is not sufficient to transfer findings from rodent animal studies on fat loss to humans.
The CB4211 Phase 1b/2a trial explored the efficacy of a modified version of MOTS-c (not the original one) and used doses established from the Phase 1 pharmacokinetic study, though public reports do not reveal the exact dosages being used. The MOTS-MET Phase 2a trial is focused on applying native MOTS-c via subcutaneous injections for a period of 12 weeks without revealing the dosage in its public documentation. The 5-10 mg dosage claims made in the research papers of the community result from extrapolation made from animal studies and the CB4211 program without references to any human dosing studies.
MOTS-c has not been approved by the FDA for use as a drug. As of the mid-2026 period, its 503A compounding status is still under review. MOTS-c is completely banned by WADA under S4.4.1 (AMPK activators, metabolic modulators) both during and outside of competition. USADA adheres to the WADA list and does not grant TUEs for MOTS-c use. Therefore, any athlete using MOTS-c will be violating anti-doping regulations.
AOD-9604 appears to be a modified C-terminal fragment of human growth hormone (it consists of amino acid sequence from 177 to 191 plus tyrosine at the N-terminal part) which promotes lipolysis and inhibits lipogenesis via beta-3 adrenergic receptors in adipose tissue. MOTS-c is a mitochondrial-encoded peptide that activates AMPK in a systemic manner. Both compounds are not raising IGF-1 level. AOD-9604 is already through Phase 2 human trials, where it has been shown safe but not effective in regards to losing weight; on its side MOTS-c is under Phase 2a trial. In terms of FDA regulations, AOD-9604 is rated as 503A Category 2 (compounding banned) while MOTS-c is still undergoing a review. In accordance with the World Anti-Doping Agency (WADA) regulations, AOD-9604 is prohibited in the WADA S2 category (GH fragments) while for MOTS-c there is a prohibition according to WADA S4.4.1 section (AMPK activators). Both compounds belong to different class of drugs and differ in terms of mechanism of action and regulatory history as well as the base of evidence.
Professionals who are investigating fat-metabolism and metabolic-modulating substances can find the complete catalog available at US Peptide Labs - GLP-1 and Weight Management where each vial arrives with AxisPharm's COA, and shipping within the US is free for purchases over $70. All of the items are meant for laboratory research purposes only, 21+.